文献速递头颈外科

涎腺癌切除及颈淋巴结清扫术后辅助治疗对生存的影响

Survival Impact of Adjuvant Therapy in Salivary Gland Cancers following Resection and Neck Dissection.
PubMed 文献 · Otolaryngol Head Neck Surg · 2019-02-05

基于美国国家癌症数据库2004至2013年接受治愈性局部切除及颈淋巴结清扫的4145例涎腺癌患者,中位随访54个月。多因素分析显示术后放疗与总生存改善相关,而辅助化疗与生存改善无关。

要点

  • 术后放疗与涎腺癌患者总生存改善相关,诊断后≤9个月HR 0.26,>9个月HR 0.75。
  • 倾向性评分匹配队列中,术后放疗组5年总生存67.1%,观察组60.6%(P < .001)。
  • 辅助化疗与生存改善无关(HR 1.15;95% CI,0.99-1.34;P = .06)。

核心结论

  • 术后放疗而非化疗与需要颈淋巴结清扫的涎腺癌患者生存改善相关,该结果不适用于无需颈淋巴结清扫的低危涎腺癌。

研究设计与样本

  • 回顾性人群队列研究,数据来自美国国家癌症数据库,纳入2004年至2013年接受手术的涎腺癌患者,要求颈淋巴结清扫至少切除10枚淋巴结,共4145例符合纳入标准,中位随访54个月。

主要发现

  • 多因素分析中,术后放疗与总生存改善相关,诊断后≤9个月HR 0.26(95% CI,0.20-0.34;P < .001),>9个月HR 0.75(95% CI,0.66-0.86;P < .001)。
  • 倾向性评分匹配队列中,术后放疗组5年总生存67.1%,观察组60.6%(P < .001)。
  • 对诊断后生存至少6个月的患者进行界标分析,观察到相似结果。
  • 辅助化疗与生存改善无关(HR 1.15;95% CI,0.99-1.34;P = .06)。

临床怎么用

  • 作者结论认为,对于需要颈淋巴结清扫的涎腺癌患者,术后放疗与生存改善相关,而化疗与生存改善无关,该结果不适用于无需颈淋巴结清扫的低危涎腺癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the impact of postoperative radiotherapy (PORT) and chemotherapy on survival in salivary gland cancer (SGC) treated with curative-intent local resection and neck dissection. STUDY DESIGN: Retrospective population-based cohort study. SETTING: National Cancer Database. SUBJECTS AND METHODS: Patients with SGC who were undergoing surgery were identified from the National Cancer Database between 2004 and 2013. Neck dissection removing a minimum of 10 lymph nodes was required. Because PORT violated the proportional hazards assumption, this variable was treated as a time-dependent covariate. RESULTS: Overall, 4145 cases met inclusion criteria (median follow-up, 54 months). PORT was associated with improved overall survival in multivariable analysis, both ≤9 months from diagnosis (hazard ratio [HR], 0.26; 95% CI, 0.20-0.34; P < .001) and >9 months (HR, 0.75; 95% CI, 0.66-0.86; P < .001). In propensity score-matched cohorts, 5-year overall survival was 67.1% and 60.6% with PORT and observation, respectively ( P < .001). Similar results were observed in landmark analysis of patients surviving at least 6 months following diagnosis. Adjuvant chemotherapy was not associated with improved survival (HR, 1.15; 95% CI, 0.99-1.34; P = .06). CONCLUSION: PORT, but not chemotherapy, is associated with improved survival among patients with SGC for whom neck dissection was deemed necessary. These results are not applicable to low-risk SGCs not requiring neck dissection.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Aro K, Ho AS, Luu M, et al. Survival Impact of Adjuvant Therapy in Salivary Gland Cancers following Resection and Neck Dissection. Otolaryngol Head Neck Surg. 2019. PMID: 30721113. doi:10.1177/0194599819827851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。